Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Cell Signal. 2022 Aug 25;99:110450. doi: 10.1016/j.cellsig.2022.110450

Fig. 7.

Fig. 7.

Effect of p38 inhibitor (SCIO469) on hypoxia-induced erythrocyte dehydration and sickling in mouse models of sickle cell disease. Erythrocytes from two strains of sickle cell disease including Hbatm1PazHbbtm1TowTg(HBA-HBBs)41Paz/J (Berkeley; N = 4; Panels A–C) and B6;129-Hbatm1(HBA)TowHbbtm2(HBG1,HBB*)Tow/Hbbtm3(HBG1,HBB)Tow/J (Towne; N = 4; Panels D–F) were incubated under hypoxia in the presence of a p38 MAPK inhibitor (SCIO469, 100 μmol/L) or with vehicle control (H2O 0.1%) and later evaluated for erythrocyte phenotype (percent sickle and non-sickle) as described in Methods. Representative images are shown for vehicle controls (A, D) and SCIO469-treated erythrocytes (B, E). Bar graphs (C and F) represent the percent (mean with SEM) of sickle erythrocytes overlaid with non-sickle. Data were collected from 2 independent experiments. ***p = 0.0006 (C) and *p = 0.0247 (D) by paired t-test (non-sickle phenotype SCIO469 versus vehicle control).